One area of immediate interaction is digestion, as GLP-1 therapies slow gastric emptying, potentially delaying the onset of edible cannabis effects and increasing the risk of users consuming additional doses too soon, leading to stronger-than-expected highs
Light GA, Braff DL (2005b)
[4] [5] For weight management, NICE technology appraisals (TA875 for Wegovy, TA664 for Saxenda) specify these treatments should be used within specialist weight management services (tier 3 or 4), with specific eligibility criteria, time-limited use, and defined stopping rules
Addressing polypharmacy and comorbidities If you take several medications, have them all reviewed before starting GLP-1 therapy
Arch Pharm Res
Rapid weight loss with GLP-1/GIP agents may lead to lean mass reduction, which could be concerning in RA patients already at risk for sarcopenia